Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) vs. Exemestane (AROMASIN) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy

Trial Profile

A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) vs. Exemestane (AROMASIN) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Fulvestrant (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EFECT
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Jun 2018 Results of a retrospective analysis (n=244) assessing the role of serum thymidine kinase-1 (TK1) activity in HR+ advanced breast cancer using serum samples of patients from this study cohort, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 28 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 18 Aug 2014 Planned End Date changed from 1 Dec 2012 to 1 Sep 2014, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top